Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
121 people get RXL articles and Market Currents by email alert.
Get email alerts on RXL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Healthcare ETFs Look To Supreme Court RulingTom Lydon • Wed, Nov 16, 2011 -
-
-
Best In Class Healthcare And Biotech ETFsBarchart's ETF Recommendations • Tue, Sep 20, 2011 -
-
-
-
-
Why Health Care ETFs May Be in the ClearTom Lydon • Wed, Nov 10, 2010
-
-
-
-
-
-
Don Dion: Thoughts on Leveraged ETFsDon Dion • Wed, Nov 11, 2009 -
-
Roger Nusbaum: Thoughts on Leveraged ETFsRoger Nusbaum • Wed, Nov 11, 2009
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
Healthcare ETFs Look To Supreme Court RulingTom Lydon • Wed, Nov 16, 2011
-
-
-
Best In Class Healthcare And Biotech ETFsBarchart's ETF Recommendations • Tue, Sep 20, 2011
-
-
-
-
-
Why Health Care ETFs May Be in the ClearTom Lydon • Wed, Nov 10, 2010
-
-
-
-
-
Don Dion: Thoughts on Leveraged ETFsDon Dion • Wed, Nov 11, 2009
-
-
Roger Nusbaum: Thoughts on Leveraged ETFsRoger Nusbaum • Wed, Nov 11, 2009
-
On the Risks of Using Leveraged ETFsRussell Bailyn • Tue, Oct 13, 2009
There are no Transcripts on RXL.
-
at MarketWatch.com (Nov 9, 2011)
RXL vs. ETF Alternatives
RXL Description
ProShares Ultra Health Care seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Dow Jones U.S. Health Care IndexSM.
See more details on sponsor's website
See more details on sponsor's website
Sector: Healthcare
Country: United States
Key Info
- In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
- Asset Class Performance: Sectors
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
- Wednesday, June 27, 2012, 3:05 PM Have a hankering to play the Obamacare ruling? It's risky, but if you must, here are a couple non-levered long-only ETF's ideas that traders are currently focused on: The Health Care Select Sector SPDR (XLV +1.1%) and the iShares Dow Jones U.S. Medical Devices Index Fund (IHI +1.6%). For the aggressive type, there are levered ETF's like: ProShares Ultra Health Care ETF (RXL +2.4%), or the Direxion Daily Healthcare Bull 3X Shares (CURE +4.5%). The tools are out there, how you use them is all up to you. Comment! [Healthcare, On the Move]
There are no StockTalks on this stock yet.